Catalyst Pharmaceuticals
| Company type | Public |
|---|---|
| Nasdaq: CPRX Russell 2000 Component S&P 600 Component | |
| Industry | Biotechnology |
| Founder | Patrick J. McEnany |
| Headquarters | Coral Gables, Florida, U.S. |
Key people | Patrick J. McEnany (chairman Richard Daly (CEO and Board member) |
| Products | FIRDAPSE® (amifampridine) Tablets 10 mg (commercialized 2019) AGAMREE® (vamorolone) Oral suspension 40mg/ ml FYCOMPA® (perampanel) CIII |
| US$ 86.8 million (2023) | |
| Total assets | US$ 700 million (2023) |
| Total equity | US$ 302.9 million (2023) |
Number of employees | 176 |
| Website | www.catalystpharma.com |
| Footnotes / references | |
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Firdapse commercially launched in January 2019.